Safety and Efficacy of Chyawanprash as a Prophylaxis Treatment for COVID-19: A Systematic Review and Meta-Analysis of Randomized Control Trials.

Publication date: Oct 01, 2024

Amidst the multifaceted challenges posed by COVID-19, interest in complementary and alternative medicine (CAM) has risen. Chyawanprash (CP), an Ayurvedic formulation, is recognized for its multifunctional properties. This systematic review aims to evaluate its safety and effectiveness as a COVID-19 prophylactic. A literature search was conducted for articles published within the past three years from databases such as Cochrane Library, PubMed, and Google Scholar. A total of 1008 articles were identified, and 34 were included for full-text screening, resulting in five randomized controlled trials (RCTs) meeting the eligibility criteria. Meta-analysis was performed using a random effects model, with results represented in odds ratio (95% confidence intervals (CIs)), and publication bias presented through funnel plots. The five clinical trials conducted in India analyzed 153,343 participants. In the meta-analysis, the odds ratios for COVID-19-positive patients, COVID-19-positive in symptomatic patients, healthcare resource utilization (HCRU), and adverse events were 0. 45 (95% CI 0. 06-3. 08, p = 0. 41), 0. 37 (95% CI 0. 01-12. 86, p = 0. 58), 0. 95 (95% CI 0. 18-5. 04, p = 0. 95), and 0. 94 (95% CI 0. 63-1. 40, p = 0. 75) respectively. Notably, significant heterogeneity was observed among studies including both COVID-19-positive cases (I= 80%, p = 0. 007) and symptomatic COVID-19 cases (I= 83%, p = 0. 01), whereas non-significant zero heterogeneity was observed in HCRU (I= 0%, p = 0. 74) and adverse events (I= 0%, p = 1. 00). The meta-analysis reveals a trend in the efficacy of CP as prophylaxis for COVID-19 treatments. However, owing to high heterogeneity and bias, further research is recommended.

Open Access PDF

Concepts Keywords
Google chyawanprash
Healthcare complementary alternative medicine
Library covid-19
hcru
srma

Semantics

Type Source Name
disease MESH COVID-19
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
drug DRUGBANK Ginseng
drug DRUGBANK Honey
disease IDO intervention
disease MESH Inflammation
disease IDO country
disease IDO colony
disease MESH morbidities
disease MESH hepatitis
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH malignancy
disease IDO history
disease MESH hypersensitivity
disease MESH diabetes mellitus
disease IDO immunodeficiency
disease MESH infection
drug DRUGBANK Chloroquine
disease MESH comorbidity
disease MESH contraindications
drug DRUGBANK Ocimum tenuiflorum top
drug DRUGBANK Water
drug DRUGBANK Oxygen
disease MESH gastritis
disease MESH complications

Original Article

(Visited 1 times, 1 visits today)